Abatacept in Immune Checkpoint Inhibitor Myocarditis

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2022
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Epistemonikos ID: e0c5dfffd8e122343b7e314e60ef433cfd6d4452
First added on: Oct 02, 2023